Overview of existing Remimazolam partnerships

Cosmo Pharmaceuticals

In June 2016, PAION and Cosmo Pharmaceuticals announced a license agreement for Remimazolam. Cosmo was granted the exclusive development, production, and marketing rights to Remimazolam for the U.S. market in return for making an upfront payment to PAION and undertaking to pay PAION milestone payments and possible future royalties.

 

Additional information is available here:
PAION grants Cosmo Pharmaceuticals Remimazolam license in the U.S. and Cosmo becomes largest Shareholder of PAION AG (press release, June 2016)

Hana Pharm

In October 2013, PAION and Hana Pharm announced a license agreement for Remimazolam. Hana Pharm was granted the exclusive development, production, and marketing rights to Remimazolam for South Korea in return for making an upfront payment to PAION and undertaking to pay PAION milestone payments and possible future royalties.

 

Additional information is available here:
PAION AG grants license to Hana Pharm for Remimazolam in South Korea (press release, October 2013)

Pendopharm

In July 2014, PAION and Pendopharm announced a license agreement for Remimazolam. Pendopharm was granted the exclusive development and marketing rights to Remimazolam for Canada in return for undertaking to pay PAION milestone payments and possible future royalties.

 

Additional information is available here:
PAION grants license to Remimazolam in Canada to Pendopharm (press release, July 2014)

R Pharm / TR-Pharm

In October 2013, PAION and R Pharm announced a license agreement for Remimazolam. R Pharm was granted the exclusive development, production, and marketing rights to Remimazolam for Russia (CIS) in return for making an upfront payment to PAION and undertaking to pay PAION milestone payments and royalties.

 

In November 2013, PAION and TR-Pharm, a subsidiary of R Pharm, announced a license agreement for Remimazolam. TR-Pharm was granted the exclusive development, production, and marketing rights to Remimazolam for Turkey and the MENA region (Middle East and North Africa) in return for making an upfront payment to PAION and undertaking to pay PAION milestone payments and royalties.

 

Additional information is available here:
PAION AG grants license to R-Pharm for Remimazolam in Russia (CIS) (press release, October 2013

PAION grants license for Turkey to add to R-Pharm territory (press release, November 2013)

PAION grants license for “MENA Region” to R-Pharm (press release, June 2014)

Yichang Humanwell Pharmaceutical Co.

In July 2012, PAION and Yichang Humanwell announced a license agreement for Remimazolam. Yichang Humanwell was granted the exclusive development, production, and marketing rights to Remimazolam for the Chinese market in return for making an upfront payment to PAION and undertaking to pay PAION milestone payments and possible future royalties.

 

Additional information is available here:
PAION AG grants license to YICHANG Humanwell for Remimazolam in China (press release, July 2012)